Cargando…

Excellent Response to Olaparib in a Patient with Metastatic Pancreatic Adenocarcinoma with Germline BRCA1 Mutation after Progression on FOLFIRINOX: Case Report and Literature Review

Metastatic pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis. Until recently, cytotoxic chemotherapy was the only treatment option. Currently, there are subgroups of patients with PDAC either with somatic or germline mutations who are candidates for targeted agents. Germline mutations i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pimenta, Jefferson Rios, Ueda, Serli Kiyomi Nakao, Peixoto, Renata D'Alpino
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7443654/ https://www.ncbi.nlm.nih.gov/pubmed/32884538 http://dx.doi.org/10.1159/000508533

Ejemplares similares

Primary tumor resection of metastatic gastric cancer in a multimodal era: Two case reports
por: Takeda, Flavio Roberto, et al.
Publicado: (2020)

Cost-Effectiveness Analysis of Olaparib Maintenance Treatment for Germline BRCA-Mutated Metastatic Pancreatic Cancer
por: Li, Na, et al.
Publicado: (2021)

BRCA 1/2 Germline Mutation Predicts the Treatment Response of FOLFIRINOX with Pancreatic Ductal Adenocarcinoma in Korean Patients
por: Park, Ji Hoon, et al.
Publicado: (2022)

Case report: olaparib use in metastatic lung adenocarcinoma with BRCA2 pathogenic variant
por: Soon Jian Hao, Jonathan, et al.
Publicado: (2022)

Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report
por: Ma, Yi, et al.
Publicado: (2018)

Successful treatment of refractory lung adenocarcinoma harboring a germline BRCA2 mutation with olaparib: A case report
por: Zhang, Li, et al.
Publicado: (2021)

Clinical Response to Sorafenib in a Patient with Metastatic Colorectal Cancer and FLT3 Amplification
por: Moreira, Raphael Brandão, et al.
Publicado: (2015)

Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib
por: Hammel, P, et al.
Publicado: (2019)

Olaparib is effective for recurrent urothelial carcinoma with BRCA2 pathogenic germline mutation: first report on olaparib response in recurrent UC
por: Yang, Hong, et al.
Publicado: (2020)

Treatment Options for Germline BRCA-Mutated Metastatic Pancreatic Adenocarcinoma
por: Grzelak, Doreen
Publicado: (2021)

Pancreatic cancer patients with germline BRCA mutations can benefit from olaparib treatment
por: Mukherjee, Shibani, et al.
Publicado: (2020)

Olaparib and somatic BRCA mutations
por: George, Angela, et al.
Publicado: (2017)

Recurrent uterine serous carcinoma with a germline pathogenic BRCA2 variant treated using olaparib: A case report
por: Inoue, Kayo, et al.
Publicado: (2020)

Response to Olaparib in a Patient with Germline BRCA2 Mutation and Breast Cancer Leptomeningeal Carcinomatosis
por: Exman, Pedro, et al.
Publicado: (2019)

Clinical Activity and Safety of Cediranib and Olaparib Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma without BRCA Mutation
por: Kim, Joseph W., et al.
Publicado: (2021)

An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma
por: Péron, Julien, et al.
Publicado: (2016)

Unresectable metastatic colorectal cancer in fit patients – a practical algorithm of treatment sequencing from the Brazilian Group of Gastrointestinal Tumours (GTG)
por: Peixoto, Renata D’Alpino, et al.
Publicado: (2023)

Exceptional Response to Olaparib and Pembrolizumab for Pancreatic Adenocarcinoma With Germline BRCA1 Mutation and High Tumor Mutation Burden: Case Report and Literature Review
por: Lundy, Joanne, et al.
Publicado: (2022)

Adjuvant Olaparib for Germline BRCA Carriers With HER2-Negative Early Breast Cancer: Evidence and Controversies
por: Morganti, Stefania, et al.
Publicado: (2023)

MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib
por: Whicker, Margaret E., et al.
Publicado: (2016)

A case report of a dramatic response to olaparib in a patient with metastatic pancreatic cancer harboring a germline BRCA2 mutation
por: Wang, Huan, et al.
Publicado: (2019)

Cost-Effectiveness Analysis of Maintenance Olaparib in Patients with Metastatic Pancreatic Cancer and a Germline BRCA1/2 Mutation Based on the POLO Trial
por: Zhan, Mei, et al.
Publicado: (2020)

Prolonged response on olaparib maintenance in metastatic pancreatic acinar cell carcinoma associated with a germline BRCA 2 mutation, revealed by severe panniculitis
por: Lelong, Margaux, et al.
Publicado: (2022)

Human Epidermal Growth Factor Receptor 2-Positive Duodenal Adenocarcinoma: A Case Report and Review of the Literature
por: Braga, Virginia Moreira, et al.
Publicado: (2015)

Response of germline BRCA2-mutated advanced pancreatic acinar cell carcinoma to olaparib: A case report
por: Li, Mao, et al.
Publicado: (2018)

Epididymitis following Cytoreductive Surgery with Intraperitoneal Oxaliplatin Chemotherapy: Two Case Reports
por: Barbosa, Luiza Damian Ribeiro, et al.
Publicado: (2016)

Metastatic lung adenocarcinoma with BRCA2 mutation and longstanding disease control on olaparib, developing triple negative breast adenocarcinoma with additional BRCA2 reversion mutation: a case report
por: del Giglio, Auro, et al.
Publicado: (2023)

Metastatic Breast Cancer with BRCA Mutation Discovered By Next-Generation Sequencing Responding to Olaparib
por: Rizvi, Wajeeha, et al.
Publicado: (2017)

Olaparib for metastatic breast cancer in a patient with a germline PALB2 variant
por: Kuemmel, Sherko, et al.
Publicado: (2020)

Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis
por: Im, Seock-Ah, et al.
Publicado: (2020)

Olaparib versus Placebo in Maintenance Treatment of Germline BRCA-Mutated Metastatic Pancreatic Cancer: A Cost–Utility Analysis from the Canadian Public Payer’s Perspective
por: Mirzayeh Fashami, Fatemeh, et al.
Publicado: (2023)

Tonic-Clonic Seizure following Cytoreductive Surgery with Intraperitoneal Oxaliplatin: A Case Report and Review of the Literature
por: Tsukamoto, Jessica Sayuri, et al.
Publicado: (2016)

Case report: Olaparib as an experimental therapy in a BRCA2-mutated patient with metastatic ovarian adenocarcinoma that originated from liver cancer
por: Li, Caixia, et al.
Publicado: (2022)

Clinical utilization of olaparib, a PARP inhibitor, in BRCA1-mutant metastatic acral melanoma
por: Jiang, Ruixin, et al.
Publicado: (2022)

Hiatal Hernia as a Total Gastrectomy Complication
por: Santos, Bruna do Nascimento, et al.
Publicado: (2016)

Olaparib combined with immunotherapy for treating a patient with liver cancer carrying BRCA2 germline mutation: A case report
por: Zhao, Fengjiao, et al.
Publicado: (2020)

Pancreatic mucinous cystadenocarcinoma in a patient harbouring BRCA1 germline mutation effectively treated with olaparib: A case report
por: Di Marco, Mariacristina, et al.
Publicado: (2020)

Rapid Disease Progression of Liver Metastases following Resection in a Liver-Transplanted Patient with Probable Lynch Syndrome – A Case Report and Review of the Literature
por: Wassano, Noelle Suemi, et al.
Publicado: (2017)

Olaparib: A Novel Therapy for Metastatic Breast Cancer in Patients With a BRCA1/2 Mutation
por: Caulfield, Sarah E., et al.
Publicado: (2019)

Targeting KRAS in Pancreatic Ductal Adenocarcinoma: The Long Road to Cure
por: de Jesus, Victor Hugo Fonseca, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_epvul3rmd86jvo3134ep0c5qnk